The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Or even thinking more left field the government are going to sell the sovereign test worldwide and maybe we receive higher royalties for rest of world and just sell everything we make to HMG. So many possibilities
Not sure that tech transfer to asian manufacturers would take that long. There is a big difference between transfering a proven prototype to manufacturing for the first time and transfering across a fully validated manufacturing process.
Perhaps the UK GOV are also offering xx months gurenteed spend in exchange for whatever price per test had been agreed.
Good point Matt. Perhaps the draw of being THE UK test of choice was too big a draw/marketing opportunity. Once this position is secured I think the globe opens up.
I think we will license out our IP/LFT to the rest of the world and receive royalty payments rather than keep direct control, Big Al likes this modus operandi
Im of the the same mindset Matt, hmg is not the golden goose some might think.
As for AVA6000 im nearly wishing this year away ffs.
The test the world needs must be accurate and easy to self test ie front of nose or saliva, nasopharyngeal tests if self administered are likely to be done incorrectly as they are soo uncomfortable.and also must be cheap for the masses.
As has been said there are loads of antigen tests around the world but there aren't many that have really high s/s with front of nose (1 or 2cm in) or saliva.
If our C/V data is the same as the clinical evaluation data then every country in the world would buy our tests if offered them.
The problem is manufacturing capicity, the government will take everything we can make as is seen with the 8 billion tender .
If we could make 40 million per month the government would still take them all.
If we want to get in to Europe and beyond we really need the giant factories in Asia to pop out close to 100 million per month which leads to the questuon of if this is the plan why are we only in talks with possible partners in SE Asia? Why are we not in the process of t/t with them as we know this will take circa 4 months, or is big Al waiting for CV before putting such deals in place?
It would be a shame if in the end if we produced the 10 million per month when there is a global market in the many many billions per year for the next 2 years .
Tho there is still many pieces of the puzzle missing as far as manufacturing capacity and the "consortium" are concerned ,I am sure everything will be revealed within the next 5 weeks and there will be a few surprises .
It's been an absolute rollercoaster of a year with avacta,and the journey has only just begun.
Here's to saving lives
Prolonging lives
Ending this pandemic
And early retirement
I think the problem is there is no standard for S&S reporting. I believe most are based on symptomatic use only. Also CT values may be different as are the collection methods, most as noted appear to be NP.
I agree that there is a lot of competition out there now but no doubt if ours is as good in the clinical trials and with asymptomatic patients then it will sell itself.
Tbh im not fully convinced we are integral to a sovereign test, i think of it as 50-50 but thats not to say we wont sell any to hmg.
There is a reasonable chance we will end up with more cash in hand than the likes of NCYT from the LFT but equally am not concerned if it turns out to be more modest.
The calm in this BB recently speaks volumes about the future potential here and I am quiety confident that Avacta will pull in at least enough revenues to propel us to the next level.
The likes of ODX and NCYT would love to have the IP of AVCT, even if they generate more revenues from the covid opportunity (i dont think they will) where next for them? We all know the opportunities here beyond covid.
The future is multiple diagostic pipelines, multiple prochemo pipelines, multple oncology pipelines, multiple big pharma , multiple billions mcap...
The future is AVACTA and potentially life changing wealth for LTH.. Dyor :)
Dictionary.com
Ignore: refuse to take notice of or acknowledge; disregard intentionally.
You got two replies. You weren't ignored.
davidpqz is one of those derampers who appear occasionally, he is of the type who pretend to be invested, often the "concerned" type
You seemed slightly miffed davidpqz that your post bringing up two other tests had originally been "studiously ignored".
Thing is that those of us who are researched are confident that no other fast antigen tests rival ours.
We know that the reason that our test zeros in on the spike protein rather than the nucleocapsid thingie is that the former avenue is potentially the most sensitive route. And the Company have told us that that as far as they are aware our test is the best rapid spike protein antigen test around.
The reason?
We have affimers they don't.
So when you post as you did yesterday or people like Merchant Banker/Okehurst big up the Vatic test on the ODX site (as they did yesterday) we no longer feel the need to furiously research and respond (although I note the polite replies you received from Vegas and Slinkey).
davidpqz, nice try but it's a brain tickler
https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/covid-19_rat_common-list_en.pdf
This was raised yesterday and has been studiously ignored. Why would Avacta have any competitive advantage over say, Ameda who already have an antigen test with near perfect sensitivity and specificity?